Claims for Patent: 5,212,204

Summary for Patent: 5,212,204

Title:	Antihypertensive compositions and use thereof
Abstract:	This invention concerns antihypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein J is an organic or inorganic moiety, M.sup.+x is a pharmaceutically acceptable cation and the compound decomposes under physiological conditions to release nitric oxide (NO).
Inventor(s):	Keefer; Larry K. (Bethesda, MD), Wink; David A. (Frederick, MD), Dunams; Tambra M. (Frederick, MD), Hrabie; Joseph A. (Frederick, MD)
Assignee:	The United States of America as represented by the Department of Health (Washington, DC)
Application Number:	07/423,279
Patent Claims:	1. An injectable pharmaceutical composition consisting essentially of a compound of the formula ##STR18## wherein J is an inorganic moiety, or an organic moiety selected from the group consisting of C.sub.1 -C.sub.12 aliphatic, C.sub.3 -C.sub.8 cycloalkyl, benzyl, phenyl, substituted benzyl, substituted phenyl, benzycarbonyl, phenylcarbonyl, substituted benzylcarbonyl, substituted phenylcarbonyl, C.sub.1 -C.sub.12 acyl, and ##STR19## wherein R is C.sub.1 -C.sub.12 aliphatic, C.sub.3 -C.sub.8 cycloalkyl, benzyl, phenyl, substituted benzyl or substituted phenyl, and said substituted benzyl and substituted phenyl is substituted with one or two substituents selected from the group consisting of halogen, hydroxy, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, amino, mono C.sub.1 -C.sub.4 alkylamino, di C.sub.1 -C.sub.4 alkyl-amino, phenyl and phenoxy; M.sup.+x is a pharmaceutically acceptable cation, wherein x is the valence of the cation, a is 1, b and c are the smallest integers that result in a neutral compound, and wherein the compound decomposes under physiological conditions to release nitric oxide (NO); and a pharmaceutically acceptable sterile carrier. 2. An injectable pharmaceutical composition consisting essentially of a compound of the formula ##STR20## wherein J is an inorganic moiety or an organic moiety; M.sup.+x is a pharmaceutically acceptacle cation, wherein x is the valence of the cation, a is 2, b and c are the smallest integers that result in a neutral compound, and wherein the compound decomposes under physiological conditions to release nitric oxide (NO); and a pharmaceutically acceptable sterile carrier. 3. The pharmaceutical composition of claim 2, wherein J is a para-phenylene, C.sub.2 -C.sub.12 alkylene, --CHR.sub.1 --, wherein R.sub.1 is H or C.sub.1 -C.sub.12 aliphatic, or ##STR21## wherein R.sup." is C.sub.1 -C.sub.6 alkylene. 4. The pharmaceutical composition of claim 1, wherein J is .sup.31 O.sub.3 S--, .sup.- O--, C.sub.1 -C.sub.12 alkyl, C.sub.5 -C.sub.6 cycloalkyl, benyzl, phenyl or ##STR22## wherein R is C.sub.1 -C.sub.12 alkyl, C.sub.5 -C.sub.6 cycloalkyl, benzyl or phenyl. 5. The pharmaceutical composition of claim 4, wherein J is .sup.- O.sub.3 S--, .sup.- O-- or phenyl. 6. The pharmaceutical composition of claim 5, wherein M.sup.30 x is a group I ion, a group II ion or .sup.+ NR.sub.2 R.sub.3 R.sub.4 R.sub.5, wherein R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently chosen from the group consisting of H, C.sub.1 -C.sub.4 alkyl, C.sub.5 -C.sub.6 cycloalkyl, phenyl and benzyl. 7. The pharmaceutical composition of claim 6, wherein M.sup.+x is Na.sup.+, K.sup.30 , Ca.sup.+2, Mg.sup.+2 or NH.sub.4.sup.+. 8. The pharmaceutical composition of claim 3, wherein M.sup.+x is a group I ion, a group II ion or +NR.sub.2 R.sub.3 R.sub.4 R.sub.5, wherein R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from the group consisting of H, C.sub.1 -C.sub.4 alkyl, C.sub.5 -C.sub.6 cycloalkyl, phenyl and benzyl. 9. The pharmaceutical composition of claim 8, wherein M.sup.+x is Na.sup.+, K.sup.30 , Ca.sup.+2, Mg.sup.+2 or NH.sub.4.sup.+. 10. The pharmaceutical composition of claim 1, wherein the compound of formula I is ##STR23## 11. The pharmaceutical composition of claim 2, wherein the compound of formula I is ##STR24## 12. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is pure sterile water, phosphate buffered saline or an aqueous glucose, solution. 13. The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier is pure sterile water, phosphate buffered saline or an aqueous glucose solution. 14. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is pure sterile water, phosphate buffered saline or an aqueous glucose solution. 15. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable carrier is pure sterile water, phosphate buffered saline or an aqueous glucose solution. 16. A method of treating cardiovascular disorders in mammals by lowering the blood pressure comprising: administering to a mammal in need thereof a blood pressure lowering effective amount of a compound of the formula ##STR25## wherein J is an organic or inorganic moiety, M.sup.+x is a pharmaceutically acceptable cation, wherein x is the valence of the cation, a is 1 or 2, b and c are the smallest integers that result in a neutral compound, and wherein the compound decomposes under physiological conditions to release nitric oxide (NO). 17. The method of claim 16 wherein the cardiovascular disorder is chronic hypertension, crisis, acute congestive heart failure, angina, acute myocardial infarction, left ventricular failure, cerebrovascular insufficiency or intracranial haemorrhage. 18. The method of claim 17 wherein the cardiovascular disorder is hypertensive crisis, acute congestive heart failure or acute myocardial infarction. 19. The method of claim 16 wherein a is 1 and J is selected from the group consisting of .sup.- O.sub.3 S--, .sup.- O--, C.sub.1 -C.sub.12 aliphatic, C.sub.3 -C.sub.8 cycloalkyl, benzyl, phenyl, substituted benzyl, substituted phenyl, benzylcarbonyl, phenylcarbonyl, substituted benzycarbonyl, substituted phenylcarbonyl, C.sub.1 -C.sub.12 acyl and ##STR26## wherein R is C.sub.1 -C.sub.12 aliphatic, C.sub.3 -C.sub.8 cycloalkyl, benzyl, phenyl, substituted benzyl or substituted phenyl, said substituted benzyl and said substituted phenyl being substituted with one or two substituents selected from the group consisting of halogen, hydroxy, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, amino, mono-C.sub.1 -C.sub.4 alkylamino, di-C.sub.1 -C.sub.4 alkylamino, phenyl and phenoxy. 20. The method of claim 16 wherein a is 2, and J is paraphenylene, C.sub.2 -C.sub.12 alkylene, --CHR.sub.1 --, wherein R.sub.1 is H or C.sub.1 -C.sub.12 aliphatic, or ##STR27## wherein R" is C.sub.1 -C.sub.6 alkylene. 21. The method of claim 19 wherein J is .sup.- O.sub.3 S--, .sup.- O--, C.sub.1 -C.sub.12 alkyl, C.sub.5 -C.sub.6 cycloalkyl, benzyl, phenyl or ##STR28## wherein R is C.sub.1 -C.sub.12 alkyl, C.sub.5 -C.sub.6 cycloalkyl, benzyl or phenyl. 22. The method of claim 21 wherein J is .sup.- O.sub.3 S--, .sup.- O-- or phenyl. 23. The method of claim 22 wherein M.sup.+x is a group I ion, a group II ion or .sup.+NR.sub.2 R.sub.3 R.sub.4 R.sub.5, wherein R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are independently selected from the group consisting of H, C.sub.1 -C.sub.4 alkyl, C.sub.5 -C.sub.6 cycloalkyl, phenyl and benzyl. 24. The method of claim 23 wherein M.sup.+x is Na.sup.30 , K.sup.+, Ca.sup.+2, Mg.sup.+2 or NH.sub.4.sup.+. 25. The method of claim 20 wherein M.sup.+x is a group I ion, a group II ion or .sup.+ NR.sub.2 R.sub.3 R.sub.4 R.sub.5, wherein R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from the group consisting of H, C.sub.1 -C.sub.4 alkyl, C.sub.5 -C.sub.6 cycloalkyl, phenyl and benzyl. 26. The method of claim 25 wherein M.sup.+x is Na.sup.+, K.sup.30 , Ca.sup.+2, Mg.sup.+2 or NH.sub.4.sup.+. 27. The method of claim 16 wherein the compound of formula I is ##STR29##

Details for Patent 5,212,204

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23